Why Adopting GenAI Is So Difficult for Pharma Companies
In the nearly year and a half since the release of ChatGPT 3.5, both businesses and individuals alike rushed to explore Generative AI (GenAI) technologies. Many of them wanted to try while some joined because of fear of missing out or because everyone is talking about it. Adding more heat to the fire, several industry conferences and media continuously reminded us that jobs would likely be lost at scale and speedily.
Today, the GenAI frenzy has seemingly calmed at least marginally. Many companies are still facing the same questions they were a year ago: How can they take advantage of the promised cost savings and substantial efficiency gains that GenAI allegedly offers? How do they actually go about putting it into their business and functional use cases?
Many companies are struggling. There are a few reasons for this.
First, many businesses, large and small, are still grappling with how to integrate traditional AI such as rule-based algorithm and machine learning into their operations. At best, they are in an exploratory phase with traditional AL, and at worst they’re simply feeling lost.
Second, GenAI is far more complex and is geared to serve specific purposes. While it is able to write a 5,000-word report in no time, it cannot, for example, do a basic data entry task, like extracting and classifying regulatory or clinical data, that traditional AI can do easily.
Third, the longer-term implications of adopting GenAI such as the long-term costs and the impacts of current and future regulation are still uncertain.
Here’s how companies can get their bearings and figure out what to do next.
Key Considerations to Take Advantage of GenAI
Given this current state of affairs, how could businesses onboard GenAI? Here, we would like to offer a few suggestions:
Choose performance over novelty.
In our long experience working with GenAI, its performance doesn’t stem from human-like text responses in a conversational manner or a model that is trained on a vast amount of data. To get the best out of GenAI, you must ask whether it’s the right technology for a particular task or goal.
In other words, instead of unquestioningly embracing the latest AI technology, companies must understand the business problems that they are trying to solve and find the most suitable AI tool based on both the strengths and weaknesses of each of available options.
Combine GenAI with the power of vector database.
This is a new form of database that specializes in retrieving the closest matching records to best answer specific queries (as opposed to traditional databases that merely hold the records). Companies can use an GenAI such as ChatGPT to break down users’ queries, and then use a vector database to look for the best answers that match those parameters.
Put differently, GenAI by itself may not be sufficient. Depending on the problems to be tackled, it can only be half of the technology solution. The need for vector database to make GenAI truly useful means companies should expect to face even more complexity and long lead time when putting the solution together.
Never forget human-in-the-loop.
As ever, no matter how powerful AI technologies seem to be, their abilities are only as good as how much humans are involved. This is no different for GenAI. Humans play a critical role in guiding GenAI toward business goals, managing interactions within IT systems, designing the actions required for data going to and coming out of AI models as well as mitigating hallucinations the made-up or outright false information produced by GenAI that remains a major problem of GenAI today.
Have realistic expectations.
GenAI is a fast-traveling ship with a lot happening below deck. It is hard to know exactly what, how much, and how quick GenAI companies can realistically achieve. Believing with conviction that it can yield immediate results and outstanding financial returns will most likely lead to disappointments. Leaders must recognize that the exploratory and experimental journey of GenAI will likely be a long one.
The utilization of GenAI technologies in business operations transcends a mere technological investment; it’s fundamentally a business imperative. Hard as it is as an undertaking, to onboard GenAI in company operations is to understand the nuances of the current GenAI developments and have a keen awareness of the challenges presented. Yet, for those businesses that can successfully make use of GenAI to reach their business goals, the rewards can only be both promising and huge.
Get the latest updates from DDismart
Explore Topics
- Clinical Automation (8)
- Consumer Health (1)
- IRT & Clinical Supplies (17)
- Labeling (15)
- Regulations (15)
- Regulatory Automation (12)
- Regulatory Biopharma (2)
- Regulatory Content Management (5)
- Regulatory Information Management (11)
- UDI (10)
- Writing (8)
Recent Blogs
- Why Adopting GenAI Is So Diffi…Regulatory Biopharma
- The Future of eIFU: Simplifyin…Regulations
- Updates to the GUDID final Gui…UDI
Previous Post
Next Post
Related Posts
CONNECT WITH US
Let's talk about how DDi can help you